A trial that started back in 1990 continues to demonstrate a significant mortality advantage for intensive insulin therapy in heart attack (MI) patients. Although earlier trials demonstrated the benefits of intensive glucose control in type 2 diabetics, more recent trials have found no benefit …

READ FULL ARTICLE Curated publisher From Forbes